The European Medicines Agency (EMA) has recommended granting marketing authorization for Jascayd (nerandomilast, Boehringer Ingelheim International GmbH) to treat adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). The opinion will now be sent to the European Commission for a decision on an EU-wide marketing authorization. …
Read More
EMA OKs New Option for Pulmonary Fibrosis
